Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy
Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series
FILSPARI (sparsentan): Patient-reported Outcomes in the Phase 3 PROTECT Study
Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study
International IgAN Symposium 2025
September 17 - 20, 2025
Czech Republic
Sparsentan Ameliorates Glomerular Hypercellularity and Inflammatory-gene Networks Induced by IgA1-IgA Immune Complexes in a Mouse Model of IgA Nephropathy
Sparsentan: The First and Only Non-Immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
Sparsentan Is Superior to Losartan in the gddY Mouse Model 1 of IgA Nephropathy
Kidney Failure Attributed to Immunoglobulin A Nephropathy: A USRDS Retrospective Cohort Study of Epidemiology, Treatment Modalities, and Economic Burden
FILSPARI (sparsentan)Prescribing Information Update
Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile
Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT Study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Immunoglobulin A Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study (HONUS): Results for IgAN and FSGS in Europe